CN104204195B - 以记忆t细胞为主要成分的淋巴细胞群的制造方法 - Google Patents
以记忆t细胞为主要成分的淋巴细胞群的制造方法 Download PDFInfo
- Publication number
- CN104204195B CN104204195B CN201380018924.8A CN201380018924A CN104204195B CN 104204195 B CN104204195 B CN 104204195B CN 201380018924 A CN201380018924 A CN 201380018924A CN 104204195 B CN104204195 B CN 104204195B
- Authority
- CN
- China
- Prior art keywords
- cell
- lymphocyte
- culture
- memory
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 277
- 238000000034 method Methods 0.000 title claims abstract description 141
- 210000003071 memory t lymphocyte Anatomy 0.000 title claims abstract description 137
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims abstract description 311
- 230000004913 activation Effects 0.000 claims abstract description 103
- 230000008569 process Effects 0.000 claims abstract description 52
- 230000001681 protective effect Effects 0.000 claims abstract description 22
- 235000015097 nutrients Nutrition 0.000 claims description 52
- 230000015654 memory Effects 0.000 claims description 29
- 238000010257 thawing Methods 0.000 claims description 28
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 238000011081 inoculation Methods 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 12
- 238000012549 training Methods 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 39
- 239000000203 mixture Substances 0.000 abstract description 25
- 238000005138 cryopreservation Methods 0.000 abstract description 21
- 210000005259 peripheral blood Anatomy 0.000 abstract description 20
- 239000011886 peripheral blood Substances 0.000 abstract description 20
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 59
- 239000001963 growth medium Substances 0.000 description 57
- 239000000725 suspension Substances 0.000 description 48
- 239000000306 component Substances 0.000 description 35
- 229910002092 carbon dioxide Inorganic materials 0.000 description 33
- 239000006285 cell suspension Substances 0.000 description 32
- 238000003199 nucleic acid amplification method Methods 0.000 description 32
- 230000003321 amplification Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 28
- 102100033467 L-selectin Human genes 0.000 description 28
- 238000007710 freezing Methods 0.000 description 25
- 230000008014 freezing Effects 0.000 description 25
- 102000000588 Interleukin-2 Human genes 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000003306 harvesting Methods 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 210000002751 lymph Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 238000004140 cleaning Methods 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000035699 permeability Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 229920001342 Bakelite® Polymers 0.000 description 8
- 101710160107 Outer membrane protein A Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000013049 sediment Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 3
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108700025316 aldesleukin Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000004637 bakelite Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229940087463 proleukin Drugs 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 230000009979 protective mechanism Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CXUCKELNYMZTRT-UHFFFAOYSA-N 1-Ethyl-2-benzimidazolinone Chemical compound C1=CC=C2NC(=O)N(CC)C2=C1 CXUCKELNYMZTRT-UHFFFAOYSA-N 0.000 description 1
- 241001614291 Anoplistes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- -1 be equably suspended Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000003516 cell number determination Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-088926 | 2012-04-10 | ||
| JP2012088926A JP6142142B2 (ja) | 2012-04-10 | 2012-04-10 | メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法 |
| PCT/JP2013/002405 WO2013153800A1 (ja) | 2012-04-10 | 2013-04-09 | メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104204195A CN104204195A (zh) | 2014-12-10 |
| CN104204195B true CN104204195B (zh) | 2017-07-18 |
Family
ID=49327384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380018924.8A Active CN104204195B (zh) | 2012-04-10 | 2013-04-09 | 以记忆t细胞为主要成分的淋巴细胞群的制造方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP6142142B2 (ja) |
| KR (1) | KR101521484B1 (ja) |
| CN (1) | CN104204195B (ja) |
| HK (1) | HK1205181A1 (ja) |
| WO (1) | WO2013153800A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6424447B2 (ja) * | 2014-03-28 | 2018-11-21 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法、及び細胞培養システム |
| CN106796237B (zh) * | 2014-07-22 | 2018-12-04 | 株式会社癌症免疫研究所 | 末梢循环癌细胞的检测装置 |
| US10731122B2 (en) | 2015-01-30 | 2020-08-04 | Toyo Seikan Group Holdings, Ltd. | Cell culture method and cell culture apparatus |
| CN107384859A (zh) * | 2017-09-05 | 2017-11-24 | 四川新生命干细胞科技股份有限公司 | 一种高纯度nk细胞的分离培养方法 |
| AU2018368786A1 (en) * | 2017-11-17 | 2020-06-18 | Iovance Biotherapeutics, Inc. | TIL expansion from fine needle aspirates and small biopsies |
| WO2020032782A1 (ko) * | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법 |
| CN109628396B (zh) * | 2019-01-24 | 2021-03-26 | 清华大学 | 记忆性淋巴细胞群在肝癌治疗中的应用 |
| CN113005081B (zh) * | 2019-12-20 | 2023-12-19 | 苏州依科赛生物科技股份有限公司 | 一种扩增干细胞样记忆性t细胞的培养方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363681A (zh) * | 2000-12-04 | 2002-08-14 | 胡曼泰克有限公司 | 源于脐带血的活化淋巴细胞、含有所述淋巴细胞作为主要成分的制剂和制备所述制剂的方法与成套器具 |
| CN1230524C (zh) * | 2000-12-04 | 2005-12-07 | 株式会社淋巴技术 | 细胞保存液和使用该保存液的细胞保存方法 |
| EP1066833B1 (en) * | 1999-07-08 | 2008-10-01 | Lymphotec Inc. | Use of cryopreserved activated lymphocytes as a medicament |
| JP4389039B2 (ja) * | 1998-04-09 | 2009-12-24 | 株式会社リンフォテック | アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4385158B2 (ja) * | 2000-12-04 | 2009-12-16 | 株式会社リンフォテック | 細胞の保存液および該保存液を用いた細胞の保存方法 |
| ES2589678T3 (es) * | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
-
2012
- 2012-04-10 JP JP2012088926A patent/JP6142142B2/ja active Active
-
2013
- 2013-04-09 CN CN201380018924.8A patent/CN104204195B/zh active Active
- 2013-04-09 KR KR1020147027998A patent/KR101521484B1/ko not_active IP Right Cessation
- 2013-04-09 WO PCT/JP2013/002405 patent/WO2013153800A1/ja active Application Filing
-
2015
- 2015-06-09 HK HK15105468.5A patent/HK1205181A1/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4389039B2 (ja) * | 1998-04-09 | 2009-12-24 | 株式会社リンフォテック | アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット |
| EP1066833B1 (en) * | 1999-07-08 | 2008-10-01 | Lymphotec Inc. | Use of cryopreserved activated lymphocytes as a medicament |
| CN1363681A (zh) * | 2000-12-04 | 2002-08-14 | 胡曼泰克有限公司 | 源于脐带血的活化淋巴细胞、含有所述淋巴细胞作为主要成分的制剂和制备所述制剂的方法与成套器具 |
| CN1230524C (zh) * | 2000-12-04 | 2005-12-07 | 株式会社淋巴技术 | 细胞保存液和使用该保存液的细胞保存方法 |
Non-Patent Citations (2)
| Title |
|---|
| A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-cd3 monoclonal antibody and interleukin-2 use in a doptive immunotherapy of cancer patients;T Sekine 等;《BIOMED PHARMACOTHER》;19930331;第47卷(第2-3期);73-78 * |
| Ex vivo expansion of umbilical cord blood for transplantation;S.S.Tung 等;《Best Practice & Research Clinical Haematology》;20100630;第23卷(第2期);245-257 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013215141A (ja) | 2013-10-24 |
| CN104204195A (zh) | 2014-12-10 |
| HK1205181A1 (en) | 2015-12-11 |
| WO2013153800A1 (ja) | 2013-10-17 |
| KR101521484B1 (ko) | 2015-06-05 |
| KR20140145585A (ko) | 2014-12-23 |
| JP6142142B2 (ja) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104204195B (zh) | 以记忆t细胞为主要成分的淋巴细胞群的制造方法 | |
| CN104204194B (zh) | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 | |
| Schreibelt et al. | Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells | |
| KR20200010186A (ko) | 극저온 보관 방법 | |
| CN105101978B (zh) | Nk细胞强化型血液制剂的制造方法 | |
| CN106062185A (zh) | 用于自动生成遗传修饰的t细胞的方法 | |
| JP6359059B2 (ja) | 生細胞を含む生物学的薬剤の取り扱い方法 | |
| CN101506356A (zh) | 用于免疫治疗的活化淋巴细胞的制备方法 | |
| JP6073417B2 (ja) | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 | |
| CN108379569B (zh) | 高效荷载肿瘤抗原的dc疫苗及其诱导扩增肿瘤抗原特异性ctl的方法 | |
| WO2020044538A1 (ja) | ヒトリンパ球細胞培養用無血清培地 | |
| Luo et al. | The state of T cells before cryopreservation: Effects on post-thaw proliferation and function | |
| Wickström et al. | Expansion of tumor-infiltrating lymphocytes from melanoma tumors | |
| CN103173411A (zh) | 一种制备树突状细胞的方法及其试剂盒 | |
| CA3205462A1 (en) | Processing of tumor infiltrating lymphocytes | |
| JP2004002312A (ja) | 腫瘍・感染症および自己免疫疾患の予防・治療用ｈｌａ一致他人由来活性化リンパ球および該リンパ球を主成分とする製剤ならびに該製剤の製造方法、該製剤調製用キット | |
| CN102144165A (zh) | 一种刺激细胞的标准样品 | |
| Cunningham et al. | Stem-like memory T cells are generated during hollow fiber perfusion-based expansion and enriched after cryopreservation in an automated modular cell therapy manufacturing process | |
| Kozbial et al. | Automated generation of immature dendritic cells in a single-use system | |
| Hilkens et al. | In vitro generation of human tolerogenic monocyte-derived dendritic cells | |
| KR100569609B1 (ko) | 세포면역치료제의 제조를 위한 림프구 장기 보관 방법 | |
| JPWO2019245039A1 (ja) | 感染性免疫寛容を惹起するための組成物 | |
| CN109844100A (zh) | 制备天然杀伤t(nkt)细胞刺激性树突细胞的方法及制备含有nkt细胞刺激性树突细胞和nkt细胞的细胞组合物的方法 | |
| US20240132844A1 (en) | Highly Potent M-CENK Cells And Methods | |
| CN110129268A (zh) | 一种电转后pbmc的培养方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1205181 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1205181 Country of ref document: HK |